Kidney health may change how obesity drug works
NCT ID NCT07141030
First seen Nov 21, 2025 · Last updated Apr 28, 2026 · Updated 15 times
Summary
This study looks at how the drug GZR18 behaves in people with different levels of kidney function, from normal to severe impairment. About 32 overweight or obese adults will receive a single dose and be monitored for up to 50 days. The goal is to find the right dose for patients with kidney problems, not to treat the disease itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gan & Lee Pharmaceuticals
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.